Can I read Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer on EtoBox?

Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer by Hatem A. Azim; Nancy E. Davidson; Kathryn J. Ruddy is a Medicine article available to read on EtoBox.

What is Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer about?

For the hundreds of thousands of premenopausal women who are diagnosed annually with endocrine-sensitive breast cancer, treatment strategies are complex. For many, chemotherapy may not be necessary, and endocrine therapy decision making is paramount. Options for adjuvant endocrine regimens include tamoxifen for 5 years, tamoxifen for 10 years, ovarian function suppression (OFS) plus tamoxifen for 5 years, and OFS plus an aromatase inhibitor for 5 years. There are modest differences in efficacy between these regimens, with a benefit from OFS most obvious among patients with higher-risk disease; therefore, choosing which should be used for a given patient requires consideration of expected toxicities and patient preferences. An aromatase inhibitor cannot be safely prescribed without OFS in this setting. Additional research is needed to determine whether genomic tests such as Prosigna and Endopredict can help with decision making about optimal duration of endocrine therapy for premenopausal patients. Endocrine therapy side effects can include hot flashes, sexual dysfunction, osteoporosis, and infertility, all of which may impair quality of life and can encourage nonadherence with trea

Who reads Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer?

Author

Hatem A. Azim; Nancy E. Davidson; Kathryn J. Ruddy

Publisher

American Society of Clinical Oncology; American Society of Clinical Oncology (ASCO) (ISSN 1548-8748)

Published

2016

Language

EN

Field

Medicine (Health Sciences)